Schott Pharma AG KGaA (MIL:1SXP) Total Equity: €944.1 Mil (As of Mar. 2026)


MIL:1SXP Schott Pharma AG & CO KGaA MIL:1SXP
59 GF Score
Price €17.34
GF Value €27.95
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA Total Equity?

Schott Pharma AG KGaA MIL:1SXP 59 Total Equity is €944.1 Mil as of Mar. 2026. GuruFocus rates MIL:1SXP with a GF Score™ of 59/100 and a GF Value™ of €27.95 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Schott Pharma AG KGaA's total equity for the quarter that ended in Mar. 2026 was €944.1 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Schott Pharma AG KGaA Total Equity Historical Data

* Premium members only.

The historical data trend for Schott Pharma AG KGaA's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA Total Equity Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Equity
Get a 7-Day Free Trial 419.42 709.04 692.18 788.49 893.75

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 838.82 865.03 893.75 932.32 944.14
MIL:1SXP
59GF Score
Schott Pharma AG & CO KGaA MIL:1SXP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Schott Pharma AG KGaA Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Schott Pharma AG KGaA's Total Equity for the fiscal year that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=1598.646-704.897
=893.7

Schott Pharma AG KGaA's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1610.038-665.9
=944.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €944.1 Mil mean?
Schott Pharma AG KGaA (MIL:1SXP) has a Total Equity of €944.1 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Schott Pharma AG KGaA and its competitors.
Is Schott Pharma AG KGaA's Total Equity too high?
Schott Pharma AG KGaA's current Total Equity is €944.1 Mil. Overall, Schott Pharma AG KGaA has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Total Equity compare to ISRG and BDX?
Schott Pharma AG KGaA's Total Equity of €944.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Schott Pharma AG KGaA and its competitors. Schott Pharma AG KGaA's current Total Equity is €944.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (MIL:1SXP) is currently considered Significantly Undervalued. The stock's GF Value™ is €27.95, compared to a current price of €17.34 — trading 38% below its estimated fair value. The current Total Equity is €944.1 Mil. Schott Pharma AG KGaA's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Schott Pharma AG KGaA (MIL:1SXP), the current Total Equity is €944.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Schott Pharma AG KGaA (MIL:1SXP) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of €17.34 is trading 38% below its estimated GF Value™ of €27.95. GuruFocus considers Schott Pharma AG KGaA to be Significantly Undervalued.

Key valuation signals for MIL:1SXP:

  • Total Equity: €944.1 Mil
  • GF Value™: €27.95 vs. price of €17.34 (38% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the MIL:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Schott Pharma AG KGaA Business Description

Other Exchanges 1SXP:Germany1SXP:Austria
Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
59GF Score

Get the complete analysis for MIL:1SXP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.34
Price
€27.95
GF Value